欧洲抗结核药物的可及性与费用
该研究评估了WHO欧洲区域43个结核病治疗中心对结核分枝杆菌药敏试验及抗结核药物的可及性,并按中等收入和高收入国家分层。结果显示,对新的和重新利用的抗结核药物普遍缺乏药敏试验能力,部分国家缺乏基本药物可及性,且耐药结核病治疗费用高昂。
要点
- 43个国家中,36国(84%)可及贝达喹啉,24国(56%)可及德拉马尼,仅6国(14%)可及利福喷丁。
- WHO A组药物表型药敏试验可及率:左氧氟沙星75%(30/40),莫西沙星82%(33/40),贝达喹啉48%(19/40),利奈唑胺72%(29/40)。
- 广泛耐药结核病含碳青霉烯类方案仅在17/43国(40%)可及。
核心结论
- WHO欧洲区域普遍缺乏对新药和重新利用抗结核药物的药敏试验能力,部分国家缺乏基本药物可及性,耐药结核病治疗费用高昂。
研究设计与样本
- 研究调查了WHO欧洲区域耐药结核病负担最高的43个国家的43个主要结核病治疗中心,评估基因型和表型药敏试验可及性及药物和方案费用,并按中等收入和高收入国家分层。
主要发现
- 43个中心参与;WHO A组药物表型药敏试验可及率:左氧氟沙星75%(30/40),莫西沙星82%(33/40),贝达喹啉48%(19/40),利奈唑胺72%(29/40)。
- 43国中,贝达喹啉可及36国(84%),德拉马尼可及24国(56%),利福喷丁仅可及6国(14%)。
- 含碳青霉烯类的广泛耐药结核病方案仅在17/43国(40%)可及。
- 中等收入国家(n=12)中位费用:药物敏感结核病€44(范围€15-152),耐多药/利福平耐药结核病短程方案(含贝达喹啉6个月)€764(范围€542-15152),广泛耐药结核病方案(含贝达喹啉、德拉马尼和碳青霉烯类)€8709(范围€7965-11759)。
- 高收入国家(n=29)中位费用:药物敏感结核病€280(范围€78-1084),耐多药/利福平耐药结核病短程方案(含贝达喹啉6个月)€29765(范围€11116-40584),广泛耐药结核病方案(含贝达喹啉、德拉马尼和碳青霉烯类)€217591(范围€82827-320146)。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the access to comprehensive diagnostics and novel antituberculosis medicines in European countries. METHODS: We investigated the access to genotypic and phenotypic Mycobacterium tuberculosis drug susceptibility testing and the availability of antituberculosis drugs and calculated the cost of drugs and treatment regimens at major tuberculosis treatment centres in countries of the WHO European region where rates of drug-resistant tuberculosis are the highest among all WHO regions. Results were stratified by middle-income and high-income countries. RESULTS: Overall, 43 treatment centres from 43 countries participated in the study. For WHO group A drugs, the frequency of countries with the availability of phenotypic drug susceptibility testing was as follows: (a) 75% (30/40) for levofloxacin, (b) 82% (33/40) for moxifloxacin, (c) 48% (19/40) for bedaquiline, and (d) 72% (29/40) for linezolid. Overall, of the 43 countries, 36 (84%) and 24 (56%) countries had access to bedaquiline and delamanid, respectively, whereas only 6 (14%) countries had access to rifapentine. The treatment of patients with extensively drug-resistant tuberculosis with a regimen including a carbapenem was available only in 17 (40%) of the 43 countries. The median cost of regimens for drug-susceptible tuberculosis, multidrug-resistant/rifampicin-resistant tuberculosis (shorter regimen, including bedaquiline for 6 months), and extensively drug-resistant tuberculosis (including bedaquiline, delamanid, and a carbapenem) were €44 (minimum-maximum, €15-152), €764 (minimum-maximum, €542-15152), and €8709 (minimum-maximum, €7965-11759) in middle-income countries (n = 12) and €280 (minimum-maximum, €78-1084), €29765 (minimum-maximum, €11116-40584), and €217591 (minimum-maximum, €82827-320146) in high-income countries (n = 29), respectively. DISCUSSION: In countries of the WHO European region, there is a widespread lack of drug susceptibility testing capacity to new and repurposed antituberculosis drugs, lack of access to essential medications in several countries, and a high cost for the treatment of drug-resistant tuberculosis.
引用
- Günther G, Guglielmetti L, Leu C, et al. Availability and costs of medicines for the treatment of tuberculosis in Europe. Clin Microbiol Infect. 2022. PMID: 35961488. doi:10.1016/j.cmi.2022.07.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。